KZIA vs MEDP vs CRL vs PRA vs IQV vs JPM

For growth investors, Medpace Holdings, Inc.

(MEDP) is the stronger pick with 20. 0% revenue growth year-over-year, versus -98. 2% for Kazia Therapeutics Limited (KZIA). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Charles River Laboratories International, Inc. (CRL) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus Medpace Holdings, Inc. at 30. 6x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus Medpace Holdings, Inc. 's 0. 86x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +160. 4%, compared to -97. 3% for Kazia Therapeutics Limited (KZIA). Over 10 years, the gap is even starker: MEDP returned +1582% versus KZIA's -96. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ProAssurance Corporation (PRA) is the lower-risk stock at 0.

01β versus Kazia Therapeutics Limited's 2. 06β — meaning KZIA is approximately 24389% more volatile than PRA relative to the S&P 500. On balance sheet safety, ProAssurance Corporation (PRA) carries a lower debt/equity ratio of 32% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Medpace Holdings, Inc.

(MEDP) is pulling ahead at 20. 0% versus -98. 2% for Kazia Therapeutics Limited (KZIA). On earnings-per-share growth, the picture is similar: Kazia Therapeutics Limited grew EPS 65. 6% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, KZIA leads at 61. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -492. 9% for Kazia Therapeutics Limited — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -338. 5% for KZIA. At the gross margin level — before operating expenses — KZIA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus Medpace Holdings, Inc. 's 0. 86x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 14. 2x forward P/E versus 27. 5x for Medpace Holdings, Inc. — 13. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IQV: 22. 5% to $222. 22.

In this comparison, JPM (1.

9% yield) pays a dividend. KZIA, MEDP, CRL, PRA, IQV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04), +1582% 10Y return). Kazia Therapeutics Limited (KZIA) carries a higher beta of 2. 06 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MEDP: +1582%, KZIA: -96. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (KZIA (Healthcare) and MEDP (Healthcare) and CRL (Healthcare) and PRA (Financial Services) and IQV (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: KZIA is a small-cap quality compounder stock; MEDP is a mid-cap high-growth stock; CRL is a small-cap quality compounder stock; PRA is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while KZIA, MEDP, CRL, PRA, IQV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.